Johnson & Johnson (NYSE: JNJ) Q2 2020 earnings call dated July 16, 2020 Corporate Participants: Chris DelOrefice -- Vice President, Investor Relations Paul Stoffels -- Vice
Johnson & Johnson
-(JNJ)
XNYS:JNJ
Johnson & Johnson (JNJ): Postponement of procedures hits medical devices unit hard in Q2
Johnson & Johnson (NYSE: JNJ) saw revenue and earnings decline for the second quarter of 2020 but both the top and bottom
Infographic: Key numbers from Johnson & Johnson (JNJ) Q2 2020 earnings announcement
Johnson & Johnson (NYSE: JNJ) reported second quarter 2020 earnings results today. Reported sales decreased 10.8% to $18.3 billion. GAAP earnings fell
Johnson & Johnson mentioned COVID 80 times during earnings call, vs. Abbott’s 16
Global pharma giants Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) announced their earnings for Q1 2020 last week. Despite
Johnson & Johnson retaining Dividend King status lifts the overall mood of the economy
Until a couple of days back, we could only speculate on the impact of COVID-19 on the economy. Of course, the record
Johnson & Johnson (NYSE: JNJ) Q1 2020 Earnings Call Transcript
Johnson & Johnson (JNJ) Q1 2020 earnings call dated Apr. 14, 2020. Corporate Participants: Chris DelOrefice -- Vice President, Investor Relations Alex Gorsky -- Chairman, Board
A visual representation of Johnson & Johnson (JNJ) Q1 2020 earnings results
Johnson & Johnson (NYSE: JNJ) reported that its first-quarter 2020 earnings and revenue came in above the analysts' expectations citing product sales
Johnson & Johnson (NYSE: JNJ) Q4 2019 Earnings Conference Call Transcript
Johnson & Johnson (NYSE: JNJ) Q4 2019 Earnings Conference Call Jan. 22, 2020 Corporate Participants: Christopher DelOrefice -- Vice President of Investor Relations Alex Gorsky -- Chairman,
Johnson & Johnson (JNJ) beats Q4 earnings estimates, misses on revenue
Johnson & Johnson (NYSE: JNJ) topped earnings estimates for the fourth quarter of 2019 while revenues fell short of expectations. The shares
Johnson & Johnson (JNJ) Q3 earnings, sales beat Street view; stock gains
Earnings of healthcare conglomerate Johnson & Johnson (NYSE: JNJ) increased and topped the Street view in the third quarter helped by a
Johnson & Johnson (JNJ) likely to feel the pinch in Q3
Johnson & Johnson (NYSE: JNJ) is slated to release its third-quarter earnings results on Tuesday, October 15, before the market opens. The
Three companies that are haunted by multiple lawsuits
Several companies have battled lawsuits from time to time for various reasons. However, sometimes companies face thousands of lawsuits for one reason.
Johnson & Johnson tumbles on rating downgrade, after opioid ruling
Johnson & Johnson (NYSE: JNJ) continued the slide Wednesday after suffering a big loss in the previous trading session as investor mood
These deals set a new paradigm for healthcare industry
After a busy 2018, the scale of merger and acquisition activity in the healthcare industry is expected to be high this year
What’s in store for top pharma stocks this year
The stocks of leading pharmaceutical firms shifted to growth mode this year after winding up 2018 on a low note, in line
Looming opioid epidemic calls for stricter drug regulation
Though the healthcare industry is slowly waking up to the hazards of opioid-based prescription drugs, their sale continues unabated across all markets,
Johnson & Johnson set to revitalize pharma biz; eyes ‘above-market’ growth
Drug maker Johnson & Johnson (NYSE: JNJ) is all set to embark on an extensive program to strengthen the product portfolio and
Johnson & Johnson Q1 earnings slide on flat revenue growth
Healthcare giant Johnson & Johnson (JNJ) kicked off pharma earnings as it posted its first-quarter 2019 earnings on Tuesday, April 16, before the
Calendar: Earnings of Bank of America, IBM, United Airlines, PepsiCo on queue
Bank of America, IBM, United Airlines, PepsiCo and more earnings are scheduled for the week between April 15 and 19. Check out
Earnings preview: Johnson & Johnson (JNJ) to stay buoyant in Q1 despite challenges
Johnson & Johnson (NYSE: JNJ), one of the first healthcare companies to publish quarterly results this season, will be reporting March-quarter results
Axsome Therapeutics stock climbs to 34-month high
After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month high of